BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.95
-0.19 (-2.33%)
At close: Aug 1, 2025, 4:00 PM
8.05
+0.10 (1.26%)
After-hours: Aug 1, 2025, 7:54 PM EDT

Company Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases.

The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor.

The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals logo
CountryUnited States
Founded1986
IPO DateMar 3, 1994
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees580
CEOJon Stonehouse

Contact Details

Address:
4505 Emperor Boulevard, Suite 200
Durham, North Carolina 27703
United States
Phone919 859 1302
Websitebiocryst.com

Stock Details

Ticker SymbolBCRX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000882796
CUSIP Number09058V103
ISIN NumberUS09058V1035
Employer ID62-1413174
SIC Code2836

Key Executives

NamePosition
Jon P. StonehouseChief Executive Officer, President and Executive Director
Alane P. BarnesSenior Vice President, Chief Legal Officer and Corporate Secretary
Dr. Helen M. Thackray FAAP, M.D.Chief Research and Development Officer
Charles K. GayerSenior Vice President and Chief Commercial Officer
Babar GhiasChief Financial Officer and Head of Corporate Development
John D. BluthChief Communications Officer
Stephanie AngeliniChief People Officer
Dr. William P. Sheridan MBBSChief Development Officer
Dr. Yarlagadda S. Babu Ph.D.Chief Discovery Officer
Jinky Ang RosselliChief Data and Insights Officer

Latest SEC Filings

DateTypeTitle
Jul 31, 20258-KCurrent Report
Jul 7, 20258-KCurrent Report
Jun 30, 20258-KCurrent Report
Jun 27, 20258-KCurrent Report
Jun 25, 20258-KCurrent Report
Jun 16, 20258-KCurrent Report
Jun 4, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 14, 20258-KCurrent Report
May 6, 202510-QQuarterly Report